Evaluate the latest clinical data and treatment implications associated with available and emerging 1L therapies for HR+/HER2- BC to overcome endocrine resistance Employ recent advancements in biomarker analysis using plasma, for the detection of actionable mutations that impact clinical decision making in 1L therapy for HR+/HER2- BC Develop patient-centered strategies based on molecular data and clinical variables to optimize precision medicine for 1L therapy of HR+/HER2- BC to improve patient outcomes
- Provider:HMP Education
- Activity Link: https://www.hmpeducation.com/program/24-gduwo-102-2
- Start Date: 2024-12-02 06:00:00
- End Date: 2024-12-02 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - MOC Credit Details: ABS - 0.5 Point; Credit Type(s): Accredited CME (ABS)
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: General Surgery
Subscribe
Login
0 Comments
Oldest